uniQure (NasdaqGS:QURE) FY Conference Transcript

Summary of the Conference Call Company and Industry - Company: uniQure - Industry: Biotechnology, specifically focusing on gene therapies for neurodegenerative diseases such as Huntington's disease and epilepsy Key Points and Arguments Huntington's Disease and AMT-130 - Phase 3 Data: The pivotal Phase 1/2 trial for AMT-130 showed a 75% slowing of disease progression at three years, measured by the composite Unified Huntington's Disease Rating Scale (UHDRS) [10] - Total Functional Capacity: A 60% decline in disease progression was observed, which is significant for FDA approval [10] - Neurofilament Light: A decrease from baseline was noted, indicating reduced neurodegeneration, contrasting with the expected annual increase of 10%-15% [10] - Patient Cohorts: Data was pooled from 17 patients, with 12 having over three years of follow-up [3] - FDA Interactions: The FDA granted RMAT designation in early 2024 based on two-year data showing signals of slowing progression [16] - BLA Submission: The FDA expressed concerns about the Phase 1/2 study being hypothesis-generating and not pre-specifying statistical analyses, which affected the potential for BLA submission [28] - Next Steps: A Type B meeting with the FDA is planned to discuss Phase 3 study design and the use of external controls [53] Safety Profile - Safety of AMT-130: The procedure is reported to be remarkably safe, with no significant adverse events attributed to AMT-130 since December 2022 [72] - Neuroinflammation: Potential neuroinflammation is manageable with immune suppression, which will now be administered perioperatively [73] Regulatory Landscape - International Engagement: uniQure is engaging with regulators outside the U.S. for potential expedited reviews and expanded access pathways [75][78] - Patient Advocacy: Strong support from patient advocacy groups has been noted, with significant community involvement in lobbying for the therapy [86] Other Programs - AMT-260 (Temporal Lobe Epilepsy): Early data showed a 92% reduction in seizure frequency in a case study, with ongoing trials expected to provide more data soon [87] - AMT-191 (Fabry Disease): The program is in a Phase I/II study with 11 patients off enzyme replacement therapy, showing promising results [100][102] Financial Position and Partnerships - Funding Strategy: The company has a runway into the second half of 2029 and is disciplined in investment decisions, focusing on data that supports further investments [104][107] - Partnerships: Future partnerships will depend on data from existing programs and the Phase III strategy for Huntington's disease [107] Additional Important Information - Ethical Considerations: The company is considering the ethical implications of sham-controlled studies in slow-progressing diseases like Huntington's [61] - Long-term Data: The company plans to update the statistical analysis plan to include four-year assessments, which will provide further insights into treatment durability [66]